Expression of ANXA8,PGRMC1,and miR-92a in Cervical Cancer and Their Relationship with Clinicopathological Features
-
摘要:
目的 探究宫颈癌患者癌组织中膜联蛋白A8(annexin A8,ANXA8)、孕激素受体膜组分1(progesterone receptor membrane component 1,PGRMC1)以及微小核糖核酸-92a(microRNA-92a,miR-92a)的表达及其与临床病理特征的关系。 方法 收集2020年1月至2022年3月宜宾市第二人民医院接治的69例宫颈癌患者的宫颈癌和癌旁正常组织69例,采用免疫组织化学法检测ANXA8和PGRMC1阳性率,Western blot检测ANXA8和PGRMC1蛋白表达,RT-PCR法检测ANXA8和PGRMC1 mRNA以及miR-92a表达水平。此外,分析ANXA8、PGRMC1与miR-92a表达的线性相关性及其与宫颈癌患者临床病理特征的关系。 结果 宫颈癌组织中ANXA8和PGRMC1阳性率(76.81%、72.46%)高于癌旁正常组织(4.35%、7.25%),miR-92a表达量高于癌旁正常组织(P < 0.05)。FIGO分期越高、分化程度越低以及具有淋巴结转移和宫旁浸润,ANXA8和PGRMC1阳性率以及miR-92a表达量越高(P < 0.05)。 结论 ANXA8、PGRMC1和miR-92a在宫颈癌组织中高表达,与宫颈癌肿瘤分期、分化程度、转移和浸润等病理特征有关,可为宫颈癌患者的病理学评估提供可靠依据。 -
关键词:
- 宫颈癌 /
- 膜联蛋白A8 /
- 孕激素受体膜组分1 /
- 微小核糖核酸-92a /
- 临床病理特征
Abstract:Objective To investigate the expression of ANXA8, PGRMC1, and miR-92a in cervical cancer tissues and their relationship with clinicopathological features. Methods A total of 69 cervical cancer patients treated at the Second People’ s Hospital of Yibin City from January 2020 to March 2022 were included in this study. Cervical cancer tissues and adjacent normal tissues from these patients were collected for analysis. Immunohistochemistry was used to detect the positivity of ANXA8 and PGRMC1. Western blot was performed to analyze the protein expression of ANXA8 and PGRMC1. RT-PCR was used to measure the mRNA levels of ANXA8 and PGRMC1, as well as the expression level of miR-92a.The linear correlation among ANXA8, PGRMC1, and miR-92a expression levels, as well as their relationships with the clinical pathological features of cervical cancer patients, were analyzed. Results The positive rates of ANXA8 and PGRMC1 in cervical cancer tissues (76.81%, 72.46%) were significantly higher than adjacent tissues (4.35% and 7.25%), and the expression level of miR-92a was significantly higher than adjacent tissues (P < 0.05). With higher FIGO stage, lower differentiation degree, lymph node metastasis, and parametrial infiltration, the positivity rates of ANXA8 and PGRMC1 as well as the expression level of miR-92a were higher(P < 0.05). Conclusion ANXA8, PGRMC1, and miR-92a are highly expressed in cervical cancer tissues, and are related to the pathological characteristics such as tumor staging, differentiation degree, metastasis, and invasion. They can provide a reliable basis for the pathological evaluation of cervical cancer patients. -
表 1 ANXA8、PGRMC1和miR-92a在宫颈癌组织和癌旁正常组织的阳性表达[n (%)/($\bar x \pm s $)]
Table 1. Positive expression of ANXA8,PGRMC1,and miR-92a in cervical cancer and adjacent tissues [n (%)/($\bar x \pm s $)]
组织类型 n ANXA8 PGRMC1 miR-92a 阳性 阴性 阳性 阴性 癌旁正常组织 69 3(4.35) 66(95.65) 5(7.25) 64(92.75) 0.90±0.37 宫颈癌组织 69 53(76.81) 16(23.19) 50(72.46) 19(27.54) 4.58±2.08 χ2/t / 75.13 61.22 14.63 P / <0.001* <0.001* <0.001* *P < 0.05。 表 2 不同临床病理特征宫颈癌患者中ANXA8表达情况[n (%)]
Table 2. ANXA8 expression in cervical cancer patients with different clinicopathological features [n (%)]
临床病理特征 n ANXA阳性(n=53) ANXA阴性(n=16) χ2/Z P 肿瘤类型 鳞癌 45 34(75.56) 11(24.44) 0.115 0.735 腺癌 24 19(79.17) 5(20.83) FIGO分期 Ⅰ期 32 17(53.13) 15(46.88) 4.160 <0.001* Ⅱ期 17 16(94.12) 1(5.88) Ⅲ期 20 20(100.00) 0(0.00) 分化程度 高分化 11 0(0.00) 11(100.00) 6.204 <0.001* 中分化 19 14(73.68) 5(26.32) 低分化 39 39(100.00) 0(0.00) 淋巴结转移 否 38 22(57.89) 16(42.11) 16.993 <0.001* 是 31 31(100.00) 0(0.00) 宫旁浸润 无 40 24(60.00) 16(40.00) 15.102 <0.001* 有 29 29(100.00) 0(0.00) *P < 0.05。 表 3 不同临床病理特征宫颈癌患者中PGRMC1表达[n (%)]
Table 3. Expression of PGRMC1 in cervical cancer patients with different clinicopathological features [n (%)]
临床病理特征 n PGRMC1阳性(n=50) PGRMC1阴性(n=19) χ2/Z P 肿瘤类型 鳞癌 45 33(73.33) 12(26.67) 0.049 0.825 腺癌 24 17(70.83) 7(29.17) FIGO分期 Ⅰ期 32 18(56.25) 14(43.75) 3.047 0.002* Ⅱ期 17 13(76.47) 4(23.53) Ⅲ期 20 19(95.00) 1(5.00) 分化程度 高分化 11 1(9.09) 10(90.91) 5.832 <0.001* 中分化 19 11(57.89) 8(42.11) 低分化 39 38(97.44) 1(2.56) 淋巴结转移 否 38 20(52.63) 18(47.37) 16.672 <0.001* 是 31 30(96.77) 1(3.23) 宫旁浸润 无 40 22(55.00) 18(45.00) 14.547 <0.001* 有 29 28(95.55) 1(3.45) *P < 0.05。 表 4 不同临床病理特征宫颈癌患者中miR-92a表达情况($\bar x \pm s $)
Table 4. Expression of miR-92a in cervical cancer patients with different clinicopathological features ($\bar x \pm s $)
临床病理特征 n miR-92a t/F P 肿瘤类型 鳞癌 45 4.55±2.05 0.19 0.854 腺癌 24 4.64±2.18 FIGO分期 Ⅰ期 32 2.67±0.91 193.90 <0.001* Ⅱ期 17 5.17±0.57 Ⅲ期 20 7.13±0.79 分化程度 高分化 11 1.65±0.39 108.00 <0.001* 中分化 19 3.13±0.55 低分化 39 6.11±1.28 淋巴结转移 否 38 2.98±1.10 13.76 <0.001* 是 31 6.54±1.04 宫旁浸润 无 40 3.08±1.16 13.40 <0.001* 有 29 6.65±0.99 *P < 0.05。 -
[1] Liu C,Li X,Huang Q,et al. Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer[J]. Signal Transduct Target Ther,2023,8(1):44. doi: 10.1038/s41392-022-01264-9 [2] 蒋宇飞,袁蕙芸,赵文穗,等. 1973—2013年上海市长宁区宫颈癌发病率和死亡率时间趋势分析[J]. 中国肿瘤,2020,29(4):266-271. [3] Alvarado-Cabrero I,Mccluggage W G,Estevez-Castro R,et al. Micropapillary cervical adenocarcinoma: A clinicopathologic study of 44 cases[J]. Am J Surg Pathol,2019,43(6):802-809. doi: 10.1097/PAS.0000000000001245 [4] Rajaram S,Gupta B. Screening for cervical cancer: Choices & dilemmas[J]. Indian J Med Res,2021,154(2):210-220. doi: 10.4103/ijmr.IJMR_857_20 [5] Hata H,Tatemichi M,Nakadate T. Involvement of annexin A8 in the properties of pancreatic cancer[J]. Mol Carcinog,2014,53(3):181-191. doi: 10.1002/mc.21961 [6] 赵荣荣,俞泽元. ANXA8在恶性肿瘤中的研究进展[J]. 现代肿瘤医学,2022,30(22):4188-4191. [7] Zhou G Z,Sun Y H,Shi Y Y,et al. ANXA8 regulates proliferation of human non-small lung cancer cells A549 via EGFR-AKT-mTOR signaling pathway[J]. Mol Biol (Mosk),2021,55(5):870-880. [8] Yuan J B,Gu L,Chen L,et al. Annexin A8 regulated by lncRNA-TUG1/miR-140-3p axis promotes bladder cancer progression and metastasis[J]. Mol Ther Oncolytics,2021,22:36-51. doi: 10.1016/j.omto.2021.04.008 [9] Ma F,Li X,Fang H,et al. Prognostic value of ANXA8 in gastric carcinoma[J]. J Cancer,2020,11(12):3551-3558. doi: 10.7150/jca.40010 [10] Cahill M A,Neubauer H. PGRMC proteins are coming of age: A special issue on the role of PGRMC1 and PGRMC2 in metabolism and cancer biology[J]. Cancers (Basel),2021,13(3):512. doi: 10.3390/cancers13030512 [11] You J H,Lee J,Roh J L. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells[J]. J Exp Clin Cancer Res,2021,40(1):350. doi: 10.1186/s13046-021-02168-2 [12] Kamińska J,Koper-Lenkiewicz O M,Ponikwicka-Tyszko D,et al. New insights on the progesterone (P4) and PGRMC1/NENF complex interactions in colorectal cancer progression[J]. Cancers (Basel),2023,15(20):5074. doi: 10.3390/cancers15205074 [13] Ruan X,Mueck A O. Clinical importance of PGRMC1 in hormone responsive breast cancer[J]. Breast Care (Basel),2023,18(3):172-178. doi: 10.1159/000527969 [14] 周嘉禾,陈志静,李洁明,等. GRMC1在多囊卵巢综合征患者中的表达及其调控卵巢颗粒细胞凋亡和糖脂代谢的分子机制[J]. 中南大学学报(医学版),2023,48(4):538-549. [15] 林元,邓森灵,符春丽,等. 血清miR-92a及miR-224表达水平预测宫颈癌患者预后价值[J]. 中华肿瘤防治杂志,2020,27(20):1651-1656. [16] Feng S,Sun H,Zhu W. miR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway[J]. Clin Transl Oncol,2021,23(3):450-458. doi: 10.1007/s12094-020-02439-y [17] Bhatla N,Denny L. FIGO cancer report 2018[J]. Int J Gynaecol Obstet,2018,143(Suppl 2):2-3. [18] 中华人民共和国国家卫生和计划生育委员会. 宫颈癌及癌前病变规范化诊疗指南(试行)[J]. 中国医学前沿杂志(电子版),2013,5(8):37-46. [19] Mukherjee G,Biswas S,Haldar B,et al. Correlation of fine needle aspiration cytology and cell block study of category III,IV,and V (TBSRTC-2017) thyroid lesions with special reference to cytokeratin-19 immunohistochemical staining[J]. Indian J Pathol Microbiol,2022,65(3):637-641. doi: 10.4103/ijpm.ijpm_1037_21 [20] 张云清,郝文东,宋延彬,等. 宫颈癌及癌前病变组织中ANXA8、MMP2表达及临床意义[J]. 中国优生与遗传杂志,2021,29(9):1203-1207. [21] 朱连成,勾睿,郭骞,等. 膜联蛋白A8在卵巢上皮性浆液性肿瘤中的表达及临床意义[J]. 国际妇产科学杂志,2020,47(1):41-45,121. [22] Mifsud W,Bateman A. Membrane-bound progesterone receptors contain a cytochrome b5-like ligand-binding domain[J]. Genome Biol,2002,3(12):Research0068. [23] Dumitru C A,Schröder H,Schäfer F T A,et al. Progesterone receptor membrane component 1 (PGRMC1) modulates tumour progression,the immune microenvironment and the response to therapy in glioblastoma[J]. Cells,2023,12(20):2498. doi: 10.3390/cells12202498 [24] Lee S R,Lee Y H,Jo S L,et al. Absence of progesterone receptor membrane component 1 reduces migration and metastasis of breast cancer[J]. Cell Commun Signal,2021,19(1):42. doi: 10.1186/s12964-021-00719-w [25] 王恒,李江鹏,代维栋,等. miR-18a、miR-92a水平与宫颈癌患者淋巴结转移的相关性[J]. 中国性科学,2022,31(4):99-103. [26] 孙倩,王宇,邱卫强. 血清miR-92a、miR-196a表达与宫颈癌淋巴结转移的相关性[J]. 实用癌症杂志,2021,36(11):1771-1774,1782. -